<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603782</url>
  </required_header>
  <id_info>
    <org_study_id>18.03.NRC</org_study_id>
    <nct_id>NCT03603782</nct_id>
  </id_info>
  <brief_title>Ketone Plasma Kinetics After Oral Intake Of Different MCT</brief_title>
  <acronym>KetoIndex</acronym>
  <official_title>Ketone Plasma Kinetics After Oral Intake Of Different MCT Formulae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is aimed at identifying the MCT formulation matrixes that provide the
      highest ketoindex values and extended half-life, as well as to provide an initial evaluation
      of the GI tolerability of the various formula. For comparison, ketones salts and esters (food
      grade) will be also evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monocentric, open, randomized, controlled research project. The global research project will
      include several testing cycles as described in the figure 1. In each cycle, several research
      products (up to 4) will be tested on up to 20 participants in a partial or full cross-over
      design. Once cycle 1 is completed, blood parameters will be analysed and ketoindex will be
      calculated as area under the curve (AUC) of total ketones (BHB + AcA) over 4h / quantity of
      ingested MCTs in g. Based on ketoindex and ketones Thalf (T1/2: time to reach half of
      AUC-infinite of total ketones) values, new products will be developed for cycle 2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Actual">July 2, 2018</completion_date>
  <primary_completion_date type="Actual">June 29, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KetoIndex - plasma concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>KetoIndex calculated as area under the plasma concentration versus time curve (AUC) of total ketones (BHB + AcA) over 4 hours after MCT-based products consumption / quantity of ingested MCTs in gram.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total ketones (BHB+ACA) - Half-life time</measure>
    <time_frame>4 hours</time_frame>
    <description>Half-Life time (T ½) calculated as time to reach half of Area under the plasma concentration versus time curve (AUC)-infinite of total ketones (BHB+ACA) after MCT-based products consumption.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ketones blood kinetic - Plasma concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>(Total Ketones, BHB, AcA) measured as plasma concentration versus time curve (AUCs) after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketones blood kinetics - peak plasma concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Peak Plasma Concentration (Cmax) of total Ketones, BHB, AcA MCT-based products consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketones blood kinetics - time to maximum concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Time to maximum concentration (Tmax) of total Ketones, BHB, AcA MCT-based products consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketones blood kinetics - Half-life time</measure>
    <time_frame>4 hours</time_frame>
    <description>Half-Life time (T ½) measured of total Ketones, BHB, AcA after MCT-based products consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium chain fatty acid C8 and C10 - plasma concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Measure of plasma concentration versus time curve (AUCs) of Medium chain fatty acid C8 and C10 after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium chain fatty acid C8 and C10 - concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Maximum plasma Concentration (Cmax) of Medium chain fatty acid C8 and C10 (and their metabolites) after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium chain fatty acid C8 and C10 - Time to maximum concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Time to maximum concentration (Tmax) of Medium chain fatty acid C8 and C10 (and their metabolites) after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium chain fatty acid C8 and C10 - Half-life time</measure>
    <time_frame>4 hours</time_frame>
    <description>Half-Life time (T ½) measured of Medium chain fatty acid C8 and C10 (and their metabolites) after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin - plasma concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Measure of plasma concentration versus time curve (AUCs) of glucose and insuline after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin - peak plasma concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Measure of maximum plasma concentration (Cmax) of glucose and insuline after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin - time to maximum concentration</measure>
    <time_frame>4 hours</time_frame>
    <description>Measure of time to maximum concentration (Tmax) of glucose and insuline after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and insulin- Half-life time</measure>
    <time_frame>4 hours</time_frame>
    <description>Measure of Half-life time (T½) of of glucose and insuline after MCT-based products consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal tolerability assessment</measure>
    <time_frame>24 hours</time_frame>
    <description>Gastro-intestinal tolerability assessment with visual analogue scales for each symptom of interest (i.e.) 1) Abdominal discomfort , 2) Decreased appetite, 3) Gastric reflux, 4) Nausea, 5) Diarrhea, 6) Headache). Each scale are from 0 (better outcome) to 100 (worst outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event incidence</measure>
    <time_frame>24 hours</time_frame>
    <description>Adverse events incidence</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>2.5% protein</intervention_name>
    <description>2.5%</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>protein 5%</intervention_name>
    <description>5%</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>protein 10%</intervention_name>
    <description>10%</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>protein 15%</intervention_name>
    <description>15%</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>A2: Peptamen 1.5 Vanilla without Breakfast</intervention_name>
    <description>Peptamen withoug breakfast</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>B2: only breakfast (no product)</intervention_name>
    <description>only breakfast</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>C2: 5% protein with breakfast</intervention_name>
    <description>C2: 5% protein consumed with breakfast</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>D2: 5% protein 30 min before breakfast</intervention_name>
    <description>D2: 5% protein consumed 30 min before breakfast</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 18-50 years

          2. Healthy men and women, based on the medical screening visit and medical history

          3. BMI in the normal and overweight range 18.5 ≤ BMI ≤ 27.

          4. Able to understand and to sign a written informed consent prior to study entry

        Exclusion Criteria:

          1. Any medication possibly impacting the postprandial glucose and insulin response (on
             anamnesis, to the opinion of the medical expert)

          2. Any medication impacting dietary fat absorption and metabolism or impacting
             postprandial glucose and insulin response, to the opinion of the medical expert

          3. Pregnancy (on anamnesis) and/or lactation

          4. Known food allergy and food intolerance

          5. Individuals undergoing either dietary or exercise mediated weight loss program
             prescribed by a health care professional

          6. Individuals under ketogenic diets, or taking regular ketones products such as MCT,
             ketone esters or ketone salts (calcium, magnesium, sodium, potassium)

          7. Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols,
             1 dl of red or white wine, or 3 dl of bier

          8. Having given blood within the last month, or willing to make a blood donation until
             one month following the end of the study

          9. Participant having a hierarchical link with the research team members

         10. Not expected to follow the protocol.

         11. Smokers unable to stop for the day of the visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurice Beaumont, dr</last_name>
    <role>Study Director</role>
    <affiliation>Nestec Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic Unit</name>
      <address>
        <city>Lausanne 25</city>
        <state>Vaud</state>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>December 4, 2018</last_update_submitted>
  <last_update_submitted_qc>December 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

